ATA Inc. Stock News

ATAI Life Sciences N.V. (ATAI) shares closed today at 1.0% above its 52 week low of $5.90, giving the company a market cap of $997M. The stock is currently down 18.5% year-to-date, down 68.0% over the past 12 months, and down 68.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 0.7%. Trading Activity Trading volume this week was 30.2% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 6.8% lower than its 5-day moving average, 17.2% lower than its 20-day moving average, and 51.0% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -19933.1% The company's stock price performance over the past 12 months lags the peer average by -164.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

• Ermöglicht die Ausweitung der klinischen Entwicklung von PCN-101 auf die USA

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Biogen Shares Slip On Restricted Coverage For Its Alzheimer's Drug Biogen, Inc. (NASDAQ: BIIB) shares

NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorde

NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders

Witnessing an entirely new industry being created from scratch is a rare and historic event, one that brings with it tremendous opportunity for investors and entrepreneurs alike. If 2020 was the year

Investors need to pay close attention to ATAI Life Sciences (ATAI) stock based on the movements in the options market lately.

The Zacks Analyst Blog Highlights: PSY, PSIL, Atai Life Sciences, COMPASS Pathways and Field Trip Health.

Psychedelic substances are often grouped together with cannabis, but there are some important distinctions. ATAI, CMPS and FTRP are some of the best stocks in the space.

Psychedelic substances are often grouped together with cannabis, but there are some important distinctions. ATAI, CMPS and FTRP are some of the best stocks in the space.

Die erste große Initiative von atai Impact unterstützt vielversprechende Wissenschaftler:innen, das therapeutische Potenzial von psychedelischen Substanzen zu erforschen, um unerfüllten Bedarf auf

The stock price of ATAI Life Sciences NV (NASDAQ: ATAI) increased by over 11% today. This is why it happened.

• Apeiron und andere wichtige Aktionäre haben freiwillige Aktiensperrvereinbarungen geschlossen• Diese freiwillige Sperre verlängert die Handelsbeschränkungen um 24 Monate für Apeiron und 12

RL-007 wurde gut vertragen und zeigte ein klinisch bedeutsames prokognitives Profil

RL-007 was well tolerated and demonstrated a clinically meaningful pro-cognitive profile